CHINESE HERBAL DECOCTION AS A COMPLEMENTARY THERAPY FOR ATROPHIC GASTRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
| Autor: | Wanqing Liao, Zhang Xinying, Min Chen, Shu-jing Sui, Qing-cai Wang, Bo Yang, Weihua Pan, Fang Wenjie, Ming Zhong |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Complementary Therapies
Gastritis Atrophic medicine.medical_specialty Atrophic gastritis atrophic gastritis Helicobacter pylori Chinese herbal decoction meta-analysis Article law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Drug Discovery medicine Animals Humans Pathological Traditional medicine biology business.industry biology.organism_classification medicine.disease Confidence interval Study heterogeneity Complementary and alternative medicine 030220 oncology & carcinogenesis Relative risk Meta-analysis 030211 gastroenterology & hepatology business Drugs Chinese Herbal |
| Zdroj: | African Journal of Traditional, Complementary, and Alternative Medicines African Journal of Traditional, Complementary and Alternative Medicines; Vol 14, No 4 (2017); 297-319 |
| ISSN: | 2505-0044 0189-6016 |
| DOI: | 10.21010/ajtcam.v14i4.33 |
| Popis: | Background: Chinese herbal decoction (CHD) has been extensively used in the treatment of atrophic gastritis (AG) in China and other Far Eastern countries. We conducted a systematic review and meta-analysis to estimate the efficacy and safety of CHD in AG.Materials and Methods: Pubmed, Embase, Cochrane central register of controlled trials (central), VIP, China National Knowledge Infrastructure, Sinomed, Wanfang data were searched (up to December 2015). Randomized controlled trials recruiting patients with AG comparing CHD (alone or with western medicine (WM)) with WM were eligible. Dichotomous data were pooled to obtain relative risk (RR), with a 95% confidence interval (CI).Results: Forty-two articles including 3,874 patients were identified. CHD, used alone or with WM, had beneficial effect over WM in the improvement of clinical manifestations (RR=1.28; 95% CI 1.22-1.34) and pathological change (RR=1.42; 95% CI 1.30-1.54) for AG patients. However, the H. pylori eradication effect of CHD was not supported by the existing clinical evidence, because of the significant study heterogeneity (I2>50%) and inconsistency between the primary results and sensitivity analysis.Conclusions: CHD, if prescribed as a complementary therapy to WM, may improve the clinical manifestations and pathological change for AG patients. But its monotherapy for H. pylori eradication is not supported by enough clinical evidence.Keywords: atrophic gastritis; Helicobacter pylori; Chinese herbal decoction; meta-analysis |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|